Heartburn at Night Even on a PPI? What a Blinded Trial Found About Adding Alginate

Here's a frustration millions of people know well: you take your reflux pill every morning, exactly as prescribed — and the burning still shows up, especially at night. You're not imagining it, and you're not alone. Studies consistently find that a large share of people on a once-daily proton pump inhibitor (PPI) still have breakthrough symptoms. In 2016, a team of researchers ran one of the few properly blinded trials to ask a very practical question: if the pill isn't enough on its own, does adding an alginate on top actually help? On the study's night-time measure, it did. This is that study, explained plainly.

Why nighttime is the weak spot

Daytime reflux has gravity on its side — you're upright, and swallowed saliva helps clear acid from the esophagus. Lie down, and both of those defenses switch off. Acid that escapes the stomach lingers longer against the esophageal lining, which is why night reflux tends to burn worse, disturb sleep, and leave people reaching for solutions their morning pill was supposed to make unnecessary.

PPIs work by reducing how much acid the stomach makes. That helps enormously, but it doesn't change the mechanics of reflux — the stomach contents that remain can still travel where they shouldn't. An alginate works on exactly that mechanical side: it forms a floating gel raft on top of the stomach contents that physically gets in the way. (If you want to see that mechanism caught on camera, we've covered the imaging study that watched an alginate raft settle on the acid pocket.) So the two approaches are complementary in theory. This trial tested whether they're complementary in practice.

What they did

This was a randomised, double-blind, placebo-controlled trial — the more rigorous kind. Everyone in it already had reflux symptoms that a once-daily PPI was not fully controlling. That's a real and common situation, and it's exactly the population this question matters for.

The researchers took 136 such people and, on top of their usual pill, gave half of them an alginate four times a day and half a matching placebo that looked and tasted the same. Neither the patients nor the researchers knew who got which. The trial ran for one week of treatment, after a one-week lead-in to measure everyone's starting symptoms. Symptoms were tracked with a daily questionnaire.

Because it was placebo-controlled and blinded, this trial is better than most at separating a real effect from the power of expectation. That is its main strength — and with reflux symptoms, where expectation effects are notoriously strong, it matters.

What they found

The main symptom score improved more with alginate than with placebo. On the study's overall reflux score, the alginate group improved by 5.0 points versus 3.5 for placebo — a difference that was statistically significant, though modest.

The night-time result is the one worth highlighting. The number of nights with symptoms fell from 3.9 to 2.2 per week in the alginate group, while placebo barely moved — 3.6 to 3.0. That difference was significant. Going from roughly four disturbed nights a week to about two is a meaningful change for anyone whose sleep is being wrecked by reflux.

Now the honest counterweight. Not everything improved. Patient satisfaction with treatment was not significantly better with alginate, and neither was a second, broader symptom questionnaire. So the benefit showed up on some measures and not others — which is a more truthful picture than a clean sweep, and worth keeping in view.

Side effects were similar in both groups, mostly mild, with nausea and headache the most common.

What it means

For people already on a daily reflux pill who are still having symptoms, this trial offers reasonable, blinded evidence that adding an alginate can reduce the symptom burden over a week — and in particular can cut the number of nights disturbed by reflux. It fits neatly with what we know about the mechanism: the PPI reduces the acid, the alginate raft physically blocks what's left from travelling upward.

One thing to be clear about: this is an add-on story, not a replacement story. Everyone in the trial kept taking their pill. Nothing here suggests swapping a prescribed medication for anything else.

The honest limits

Several, and they matter.

It was short. One week of treatment. This says nothing about whether the benefit holds up over months, which is what most people actually care about.

The main questionnaire was not fully validated. The researchers built their symptom questionnaire specifically for this trial and say plainly that it had not been through a full validation process. They even note they cannot be certain the size of the score improvement is clinically meaningful. That is an unusually candid admission, and it deserves to be passed along rather than buried.

It was called an exploratory pilot. The authors describe it that way themselves. It is a promising first look, not a definitive verdict.

Some measures showed nothing. As above, treatment satisfaction and the broader symptom scale did not significantly favour alginate. A fair reading holds those alongside the wins.

It was industry-funded. Reckitt Benckiser — the maker of the alginate used in the study — funded the trial and supplied both the product and the placebo, and two authors received funding from the company. This is disclosed in the paper. It does not erase the blinding, which is a real strength, but it belongs in an honest summary.

The bottom line

In a blinded trial of people whose daily reflux pill was not fully doing the job, adding an alginate for a week reduced the overall symptom score and — notably — cut the number of nights with symptoms from about four to about two. The catch: it was short, used a questionnaire the authors admit was not fully validated, did not improve every measure, and was funded by the maker of the product studied. Encouraging on nights, but early.

If you're curious how alginate rafts do what they do, our overview of alginate-raft formulations covers the chemistry and safety profile, and our comprehensive guide to heartburn puts the whole treatment landscape in context.

---

Reference

Reimer C, Lødrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Alimentary Pharmacology & Therapeutics. 2016;43(8):899-909. [PubMed: 26909885]

Related reading on the ØBEX blog:

• How an Alginate Raft Stops Reflux: The Acid Pocket on Camera
• Alginate-Raft Formulations: A Safe, Natural Solution for Heartburn and Acid Reflux
• Understanding and Managing Heartburn: A Comprehensive Guide

---

This article is a plain-language summary of a published scientific paper, provided for educational purposes. It is not medical advice and is not a claim about any product. The study examined an alginate as an add-on therapy, not any brand sold here. These statements have not been evaluated by Health Canada. Do not change how you take any prescribed medication based on this article — consult a healthcare practitioner if your symptoms persist or if you have a medical condition or take medications.